Paper42902412PubMed
Nanoengineered STING agonists for cancer therapy: toward immunodynamic control.
Liu N and 7 others. J Hematol Oncol, 2026.
Cite this record
ConductScience Library. Nanoengineered STING agonists for cancer therapy: toward immunodynamic control. Papers, record 42902412. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42902412
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nanoengineered STING agonists for cancer therapy: toward immunodynamic control.
- Journal
- J Hematol Oncol
- Year
- 2026
- Publication types
- Journal Article, Review, Research Support, Non-U.S. Gov't
- Revised in PubMed
- 2026-10-31
Source PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Membrane Proteins | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| STING Protein | |
| Animals | |
| cGAS-STING Signaling Pathway | |
| Immunotherapy | |
| Nanomedicine | |
| Signal Transduction | |
| Nanoparticles |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| No. 7252117 | the Beijing Municipal Natural Science Foundation | PubMed | ||
| No. 82371842 | Natural Science Foundation of China | PubMed | ||
| No. 2024-I2M-ZH-006 | the CAMS Innovation Fund for Medical Sciences (CIFMS) | PubMed |
Source PubMed
References212
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29292386 | The ER membrane adaptor ERAdP senses the bacterial second messenger c-di-AMP and initiates anti-bacterial immunity. | Nat Immunol | 2018 | https://conductscience.org/library/papers/29292386 | PubMed |
| 2 | 38193384 | An Immunocompetent Hafnium Oxide-Based STING Nanoagonist for Cancer Radio-immunotherapy. | ACS Nano | 2024 | https://conductscience.org/library/papers/38193384 | PubMed |
| 3 | 36375786 | Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia. | Acta Biomater | 2023 | https://conductscience.org/library/papers/36375786 | PubMed |
| 4 | 38531218 | Feedback activation of CD73-Adenosine axis attenuates the antitumor immunity of STING pathway. | Biochem Biophys Res Commun | 2024 | https://conductscience.org/library/papers/38531218 | PubMed |
| 5 | 25959818 | Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. | Cell Rep | 2015 | https://conductscience.org/library/papers/25959818 | PubMed |
| 6 | 36959214 | STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. | Nat Commun | 2023 | https://conductscience.org/library/papers/36959214 | PubMed |
| 7 | 21709202 | Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21709202 | PubMed |
| 8 | 36968140 | Nanoparticle STING Agonist Reprograms the Bone Marrow to an Antitumor Phenotype and Protects Against Bone Destruction. | Cancer Res Commun | 2023 | https://conductscience.org/library/papers/36968140 | PubMed |
| 9 | 40068600 | Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. | Cancer Cell | 2025 | https://conductscience.org/library/papers/40068600 | PubMed |
| 10 | 41573551 | The cGAS-STING signaling pathway: emerging targets and challenges in breast cancer immunotherapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/41573551 | PubMed |
| 11 | 32863398 | Engineering of Nanoscale Coordination Polymers with Biomolecules for Advanced Applications. | Coord Chem Rev | 2019 | https://conductscience.org/library/papers/32863398 | PubMed |
| 12 | 40404668 | Neoantigen enriched biomimetic nanovaccine for personalized cancer immunotherapy. | Nat Commun | 2025 | https://conductscience.org/library/papers/40404668 | PubMed |
| 13 | 40854819 | Where does ISAC (immune-stimulating antibody conjugates) go from here? | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40854819 | PubMed |
| 14 | 36280710 | Intercellular transfer of activated STING triggered by RAB22A-mediated non-canonical autophagy promotes antitumor immunity. | Cell Res | 2022 | https://conductscience.org/library/papers/36280710 | PubMed |
| 15 | 34716197 | Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/34716197 | PubMed |
| 16 | 34443638 | Advances in Biomimetic Nanoparticles for Targeted Cancer Therapy and Diagnosis. | Molecules | 2021 | https://conductscience.org/library/papers/34443638 | PubMed |
| 17 | 36018392 | DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients. | Apoptosis | 2022 | https://conductscience.org/library/papers/36018392 | PubMed |
| 18 | 33372007 | Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. | Cancer Discov | 2021 | https://conductscience.org/library/papers/33372007 | PubMed |
| 19 | 40213662 | Photoactivatable immunomodulator polyprodrugs for boosting synergistic antitumor immunity of STING agonists and IDO inhibitors. | Theranostics | 2025 | https://conductscience.org/library/papers/40213662 | PubMed |
| 20 | 25642965 | Mitochondrial DNA stress primes the antiviral innate immune response. | Nature | 2015 | https://conductscience.org/library/papers/25642965 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42902412
GET https://conductscience.org/api/papers/v1/42902412/references?page=2